Imagene
Imagene AI delivers precision Oncology Intelligence through robust multimodal foundation models and proprietary real-world data, accelerating biomarker discovery, patient stratification, response prediction, and companion diagnostic development. From H&E-based molecular profiling to AI-IHC companion diagnostics, Imagene AI develops AI-powered pathology assays that translate biological insight into patient selection and diagnostic strategies. LungOI®, the first AI-based NSCLC multi-gene biomarker panel to receive a PLA code and CMS payment rate, was developed, validated, and deployed across multiple centers and laboratories globally. We collaborate with leading biopharma organizations to advance biomarker-driven programs from discovery through clinical development and deployment.
